You are leaving Medscape Education
Cancel Continue
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point

Specialty: Multispecialty
Allergy & Immunology
Anesthesiology
Business of Medicine
Cardiology
Critical Care
Dermatology
Diabetes & Endocrinology
Emergency Medicine
Family Medicine
Gastroenterology
General Surgery
Hematology - Oncology
HIV/AIDS
Hospital Medicine
Infectious Diseases
Internal Medicine
Multispecialty
Nephrology
Neurology
Ob/Gyn & Women's Health
Oncology
Ophthalmology
Orthopedics
Pathology & Lab Medicine
Pediatrics
Plastic Surgery
Psychiatry
Public Health
Pulmonary Medicine
Radiology
Rheumatology
Transplantation
Urology
Interprofessional
Shared Decision Making
Nurses
Pharmacists
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      Wednesday, December 6, 2023
      News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
       

      CME/CE Test

      Your Patient Has Primary Biliary Cholangitis: Take the Virtual Patient Challenge

      1. What is the recommended adult dosing of ursodeoxycholic acid (UDCA) for the treatment of primary biliary cholangitis (PBC)?
        8 to 10 mg/kg per day
        10 to 12 mg/kg per day
        13 to 15 mg/kg per day
        16 to 18 mg/kg per day
      2. Patients taking UCDA for PBC should undergo liver function tests at what frequency?
        Every 3 months while receiving therapy
        Every month for 3 months following start of therapy and every 6 months thereafter
        Every month for 6 months following start of therapy and every 6 months thereafter
        Every month for 1 year following start of therapy and every 6 months thereafter
      3. Susan, age 49, was diagnosed with PBC 18 months ago and has been taking UDCA 600 mg twice daily since diagnosis, which she is tolerating well. However, she is continuing to experience moderate to occasionally severe fatigue, which is limiting her ability to do activities of daily living. Her liver enzymes remain slightly elevated.
        What would be the most appropriate next step in Susan’s treatment?
        Discontinue the UDCA and start obeticholic acid (OCA)
        Continue the UDCA and add a fibrate
        Continue the UDCA and add OCA
        Increase the dose of the UDCA to 1000 mg twice daily
      4. The product labeling for OCA contains a black box warning for which of the following?
        Hepatic decompensation and failure
        Potentially fatal arrhythmia
        Renal failure
        QT prolongation
       
      Find Us On
      About
      About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
      Membership
      Become a Member About You Professional Information Newsletters & Alerts Market Research
      App
      Medscape
      WebMD Network
      Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate Medscape UK
      Editions
      English Deutsch Español Français Português UK
      All material on this website is protected by copyright, Copyright © 1994-2023 by WebMD LLC. This website also contains material copyrighted by 3rd parties.